BENGALURU (Reuters) - Indian generic drugmaker Dr Reddy's Laboratories reported fourth-quarter profit above expectations on Tuesday, driven by strong sales in its key U.S. and European markets.

The company reported a consolidated net profit after tax of 13.10 billion rupees ($156.9 million) for the quarter ended March 31, up 36.5% from last year and beating analysts' estimates of 12.42 billion rupees as per LSEG data.

($1 = 83.4933 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)